MetaCap

Bright Minds Biosciences (DRUG) vs Vanda Pharmaceuticals (VNDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vanda Pharmaceuticals (VNDA) has outperformed Bright Minds Biosciences (DRUG) over the past year, losing 28.2% versus a loss of 65.2%. Over five years, DRUG leads with a -7.3% price change compared with -79.2% for VNDA. Vanda Pharmaceuticals is the larger company by market cap ($208.3 million vs $201.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DRUG-65.18%VNDA-28.23%
+108%+16%-76%
Nov 21, 20251 yearNov 20, 2026
DRUG-18.73%VNDA-79.69%
+276%+81%-114%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DRUG versus VNDA key metrics
MetricDRUGVNDA
Share price$20.40$3.45
Market cap$201.23M$208.32M
1-day change-1.45%-6.13%
YTD return-73.86%-60.94%
1-year return-65.18%-28.23%
5-year return-7.27%-79.18%
Forward P/E—17.22
EPS (TTM)$-2.05$-4.62
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$216.10M
Revenue growth (YoY)—+8.72%
Net income (latest FY)—$-220.47M
Gross margin—93.96%
Operating margin—-69.95%
Net margin—-102.02%
52-week high$123.75$9.94
52-week low$17.40$3.42
Distance from 52-week high-83.52%-65.34%
Analyst consensusstrong_buynone
Avg. price target upside+426.18%+233.82%
Average volume173.24K1.06M
Shares outstanding9.86M60.47M
Employees26533
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VNDA has outperformed DRUG by 37.0 percentage points over the past year.

About Bright Minds Biosciences

DRUG stock →

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.

Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees

About Vanda Pharmaceuticals

VNDA stock →

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.

Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees

DRUG vs VNDA FAQ

Which is bigger, Bright Minds Biosciences or Vanda Pharmaceuticals?

Vanda Pharmaceuticals (VNDA) is larger, with a market capitalization of $208.32M compared with $201.23M for Bright Minds Biosciences (DRUG).

Which stock has performed better over the past year, DRUG or VNDA?

VNDA returned -28.23% over the past 12 months, compared with -65.18% for DRUG (price return, excluding dividends). Past performance does not predict future results.

Are Bright Minds Biosciences and Vanda Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons